Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

tial drug candidates have arisen from research activities that are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drug candidates directed at treatments for cardiovascular disease, cancer and other diseases. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

Forward-Looking Statements: Amgen

This news release contains forward-looking statements that are based on Amgen's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen's business. Unless otherwise noted, Amgen is providing this information as of May 26, 2009, and expressly disclaims any duty to update information contained in this news release.

No forward-loo
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 BioNano Genomics, ... of top research institutes, announced today that a collaboration ... Sinai resulted in the creation of the first comprehensive ... single DNA molecule methods for sequencing and genome mapping. ... provided the comprehensive analysis of the contiguous diploid human ...
(Date:6/29/2015)... June 29, 2015  Neuralstem, Inc. (NYSE MKT: CUR), ... develop small molecule and cell therapy treatments for central ... approved for listing on the NASDAQ Capital Market under ... to trade on the NYSE MKT until the market ... Capital Market is expected to commence on July 13, ...
(Date:6/29/2015)... June 29, 2015   Veracyte, Inc . (Nasdaq: ... field of molecular cytology, today announced that it has ... Top Workplaces list for the second year in a ... solely on an annual survey of Bay Area-company employees. ... the degree to which Veracyte values our employees and ...
(Date:6/26/2015)... , June 26, 2015  SeraCare Life ... diagnostics manufacturers, today announced that it has signed ... the National Cancer Institute (NCI), part of the ... and positive controls for cancer assays.  The CRADA ... and accurately quantitate control DNA biosynthetics spiked into ...
Breaking Biology Technology:BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... PRINCETON, New Jersey and SAN DIEGO,California, September 8 , ... for Continuous Process,Chemistry Technologies and for Further Global Expansion, ... investment of $3.3M,by a group of private and financial ... Graphisoft and Dave Tapolczay, CEO of Medical,Research Council Technology ...
... announced that it has appointed A.J. Whalen as Solutions Director. ... ... 8, 2008 -- www.symphony-consulting.com [Symphony Management Consulting] announced ... , , ,Mr. Whalen joins Symphony from Wellesley Information Services ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq: CTICD ; ... a letter from the Listing Qualifications Staff of ... is not in compliance with the,$50,000,000 minimum market ... Marketplace Rule 4450(b)(1)(A). Furthermore, the Company does not,comply ...
Cached Biology Technology:World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round 2Symphony Managemnt Consulting Hires New Solutions Director 2CTI Receives NASDAQ Letter 2CTI Receives NASDAQ Letter 3
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... termites use vibrations to choose the wood they eat ... in homes and also may provide insights into the ... most noise but have some signals that trigger attention ... entomologist Theo Evans says laboratory experiments have found that ...
... A team of Fox Chase Cancer Center scientists led ... genetic mutation that keeps a mouse strain from developing ... The report by Kappes and his colleagues appears in ... first discovered the mice with this naturally occurring defect ...
... 2,or ACC2, appears to turn the adipose or fat ... the animals can eat more and weigh less,than their ... appears online today in the Proceedings of the National,Academy ... mice bred to lack ACC2," said Dr. Salih,Wakil, chair ...
Cached Biology News:Termites feed through good vibrations 2Fox Chase Cancer Center scientists identify immune-system mutation 2Lack of enzyme turns fat cells into fat burners 2
Leptin Receptor Polyclonal Ab 100 ug purified rabbit anti-mouse Leptin Receptor. Tested in Western blotting....
... AccuPrime™ Pfx DNA Polymerase is ideal ... for downstream applications such as cloning ... provided by a proprietary enzyme preparation ... sp. with proofreading (3'Cut Site5' exonuclease) ...
... 177 amino acid polypeptide sequence corresponding to ... Produced by activation of a recombinant ... coli periplasm. SPECIFIC ACTIVITY:The specific activity ... mU/mg, where 1 U is the activity ...
... is a highly purified preparation qualified to ... vectors. The preparation is functionally tested for ... of detectable contaminating proteases. Prepared from human ... tests to be negative for HBsAg and ...
Biology Products: